GH Research (GHRS) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$15.1M

Net income growth (year over year)

−63.05%

Net margin

—

Return on equity

−18.79%

EPS (trailing twelve months)

−$0.99

Book value per share

$5.24

P/E (trailing twelve months)

—

Price to book

3.59

Debt to assets

3.45%

Payout ratio

—

Dividend yield

—

Company profile

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

• How do I buy stock in GH Research (GHRS)?

  GHRS trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.